This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Cancer Research Malaysia. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Chai Phei Gan: Innovator in Cancer Immunotherapy
Introduction
Chai Phei Gan is a notable inventor based in Selangor, Malaysia. He has made significant contributions to the field of cancer research, particularly in developing innovative immunogenic peptide compositions. His work aims to enhance the immune response against cancer, showcasing the potential of peptide-based therapies.
Latest Patents
Chai Phei Gan holds a patent for an immunogenic peptide composition. This invention relates to a peptide composition capable of binding with major histocompatibility complex class I molecules to induce an anti-cancer immune response in a subject. The composition includes at least a Four-jointed Box 1 peptide and a Melanoma Antigen family D4b peptide. Furthermore, the invention encompasses the use of this peptide composition and a peptide vaccine for inducing the anti-cancer immune response in the subject. He has 1 patent to his name.
Career Highlights
Chai Phei Gan is currently associated with Cancer Research Malaysia, where he continues to advance his research in cancer immunotherapy. His work is pivotal in exploring new avenues for cancer treatment, focusing on harnessing the body's immune system to fight cancer more effectively.
Collaborations
Chai Phei Gan collaborates with esteemed colleagues, including Sammuel Chee Yong Fong and San Jiun Chai. These partnerships enhance the research efforts at Cancer Research Malaysia, fostering innovation and development in cancer therapies.
Conclusion
Chai Phei Gan's contributions to cancer research through his innovative peptide compositions highlight the importance of scientific advancements in immunotherapy. His work not only reflects his dedication to improving cancer treatment but also underscores the collaborative spirit within the research community.